Myelofibrosis
Show Only Open Trials
1.
Phase 1/2, Open-label, Dose-escalation, Multi-ctr Study to Assess Safety, Tolerability, PK, & PD of Oral NS-018 in Patients w/ Primary Myelofibrosis, Post polycythemia Vera Myelofibrosis, or Post-essential Thrombocythemia Myelofibrosis
- Study Status: Open to Enrollment
- Sponsor: NS Pharma
- Disease Status and/or Stage: Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis
2.
Phase II Study of SAR302503 in Subjects Previously Treated with Ruxolitinib and with a diagnosis of Intermediate-2 or High-Risk PM, Post-PV Myelofibrosis, or Post-ET Myelofibrosis
- Study Status: Closed to Enrollment
- Sponsor: Sanofi Aventis
3.
A Phase 2 Study of LY2784544 in Patients with Myeloproliferative Neoplasms
- Study Status: Open to Enrollment
- Sponsor: Ely Lilly
- Disease Status and/or Stage: Polycythemia Vera (PV), Essential Thrombocythemia (ET), or Myelofibrosis (MF)
4.
Phase II randomized controlled trial of pegylated interferon alpha-2b in early primary myelofibrosis
- Study Status: Open to Enrollment
- Sponsor: Weill Cornell Medical College
- Disease Status and/or Stage: Low or Intermediate Stage Primary Myelofibrosis (PMF)
5.
Ruxolitinib (INCB018424) in Subjects With Primary Myelofibrosis, Post Essential Thrombocythemia-myelofibrosis and Post Polycythemia Vera-myelofibrosis
- Study Status: Closed to Enrollment
- Sponsor: Incyte Corporation
- Disease Status and/or Stage: Primary Myelofibrosis; Post Essential Thrombocythemia-myelofibrosis; Post Polycythemia Vera-myelofibrosis
